The House
Markets Edge · Huang GoodmanVirginia Beach · Atlantic coast · since 1997
On the wire

Markets Edge

Issued Wednesday, May 6, 2026 · 12:00 UTC Edition 8/day editions · 5 desks From the chopped neck
7
On the wire
$0.003per impression · vs Meta 0.007 CPM
8 monthsretention in hand · vs Meta 0.8 seconds
200brands you already own · Nike · YETI · Patagonia
Onenamed-account desk · by introduction
Ranked by the pour ISABELLA'S ISLAY HENRI IV MACALLAN 1926 LOUIS XIII PAPPY 23 JOHNNIE BLUE WELL POUR
Also crossing the wire
Showing 7 stories
ISABELLA'S ISLAY Capital Markets May 6, 8:02 AM EDT
JPMorgan Chase
The Block ↗

JPMorgan projects $130B in crypto inflows for 2025, expects acceleration in 2026

JPMorgan expects cryptocurrency inflows to rise further in 2026 after record $130 billion flowed into crypto assets during 2025.

ReadingCrypto is no longer an alternative allocation decision. It is now a liquidity and duration hedge that institutional treasuries are pricing into base case.
WatchThe first S&P 500 company to declare bitcoin holdings will trigger a cascade within 90 days.
Read full analysis → Original ↗
cryptocapital flowsinstitutional adoption2026 outlook
HENRI IV Capital Markets May 6, 8:02 AM EDT
Bullish Global
CNBC ↗

Crypto exchange Bullish priced IPO above range, shares soar on NYSE debut

Shares of Bullish soared in its NYSE debut after the crypto exchange priced its IPO above the expected range.

ReadingThe crypto infrastructure narrative has separated from token volatility. Exchanges are being valued as utilities, not speculation plays.
WatchWatch for derivatives platform IPOs in the next two quarters. If one prices above range, it signals infrastructure has become institutional commodity.
Read full analysis → Original ↗
ipocryptoexchangecapital markets
MACALLAN 1926 Venture Intelligence May 6, 8:02 AM EDT
Eikon Therapeutics
BioPharma Dive ↗

Eikon Therapeutics nets $381M in biotech IPO, riding sector's April momentum

Eikon Therapeutics closed a $381 million IPO amid a burst of biotech offerings in April, capitalizing on renewed investor appetite for life sciences.

ReadingBiotech IPO access returns, but only for firms with institutional backing and clear data packages. Founder-led plays without anchor investors remain frozen.
WatchIf a second-tier biotech without major institutional backing attempts IPO in May or June, watch the pricing outcome. That will signal whether window tightens again.
Read full analysis → Original ↗
biotechipocapital marketslife sciences
LOUIS XIII Venture Intelligence May 6, 8:02 AM EDT
Odyssey Therapeutics
Renaissance Capital ↗

Odyssey Therapeutics set to price $225M IPO for autoimmune disease biotech

Autoimmune disease biotech Odyssey Therapeutics has set terms for its $225 million IPO, with pricing scheduled for this week.

ReadingBiotech valuations have corrected 40-50% from 2021 peaks, but capital is flowing to firms with validated science. The era of price discovery for unproven mechanisms is over.
WatchTrack Odyssey's first trading day close relative to IPO price. Underpricing signals institutional demand; any pop above 20% means demand still exceeds supply for autoimmune programs.
Read full analysis → Original ↗
biotechipoautoimmuneventure
PAPPY 23 Healthcare Intelligence May 6, 8:02 AM EDT
Mobia Medical
Renaissance Capital ↗

Nerve stimulation device maker Mobia Medical prices $150M IPO this week

Mobia Medical, a nerve stimulation device manufacturer, has set terms for a $150 million IPO with pricing scheduled for this week.

ReadingNeurotech remains institutional favorite. Device companies with reimbursement pathways already mapped get capital access faster than small-molecule biotech.
WatchFirst quarterly earnings call will matter more than IPO pop. Investors want to hear patient enrollment numbers and reimbursement traction.
Read full analysis → Original ↗
medical deviceipohealthcareneurotech
JOHNNIE BLUE Luxury Sector May 6, 8:02 AM EDT
Luxury Real Estate Market
The Business Journals ↗

Luxury home sales dip 17% week-over-week; mega-deals queue for spring season

Luxury home sales declined 17% week-over-week, though big-ticket deals are on the horizon as the spring market season approaches.

ReadingLuxury real estate is regaining seasonality. For three years, deals happened year-round. The market is reverting to structural peaks in Q2 and Q3.
WatchWatch for a spike in the $10M+ segment starting mid-March. That will tell you whether spring inventory is real or whether deals shift to summer.
Read full analysis → Original ↗
luxuryreal estatemarket timingseasonal
WELL POUR Luxury Sector May 6, 8:02 AM EDT
South Florida Luxury Market
San Francisco Chronicle ↗

Pacific Heights mansion hits $56M, highest S.F. sale since 2024

A Pacific Heights mansion in San Francisco sold for $56 million, marking the priciest home sale in the city since 2024.

ReadingThe $50M+ segment remains insulated from mid-market weakness. Ultra-wealthy buyers operate on different pricing power and timeline.
WatchIf two more $50M+ closings happen in San Francisco within 60 days, it signals the segment has stabilized after 18 months of flat activity.
Read full analysis → Original ↗
luxury real estatesan franciscomega dealultra-high-net-worth